Xellia Pharms Aps Company Profile

✉ Email this page to a colleague

XELLIA PHARMS APS has fourteen approved drugs.

There are eight US patents protecting XELLIA PHARMS APS drugs.

There are fifty patent family members on XELLIA PHARMS APS drugs in thirty countries and twenty-six supplementary protection certificates in nine countries.

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xellia Pharms Aps	DAPTOMYCIN	daptomycin	POWDER;INTRAVENOUS	217415-002	Jan 30, 2023		RX	Yes	Yes	11,759,497	⤷ Subscribe	Y			⤷ Subscribe
Xellia Pharms Aps	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	SOLUTION;INTRAVENOUS	211962-006	May 13, 2020		RX	Yes	Yes	10,039,804	⤷ Subscribe	Y			⤷ Subscribe
Xellia Pharms Aps	CASPOFUNGIN ACETATE	caspofungin acetate	POWDER;INTRAVENOUS	205923-001	Jul 2, 2018		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Xellia Pharms Aps	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	SOLUTION;INTRAVENOUS	211962-002	Feb 15, 2019		RX	Yes	Yes	10,039,804	⤷ Subscribe	Y			⤷ Subscribe
Xellia Pharms Aps	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	SOLUTION;INTRAVENOUS	211962-005	May 13, 2020		RX	Yes	Yes	11,628,200	⤷ Subscribe	Y			⤷ Subscribe
Xellia Pharms Aps	VANCOMYCIN	vancomycin	SOLUTION;INTRAVENOUS, ORAL	213895-001	Aug 26, 2021		DISCN	Yes	No	11,517,609	⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Subscribe
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0536515	SPC/GB06/033	United Kingdom	⤷ Subscribe	PRODUCT NAME: TIGECYCLINE
1115417	SPC/GB06/024	United Kingdom	⤷ Subscribe	SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021.
0536515	2006/030	Ireland	⤷ Subscribe	PRODUCT NAME: TIGECYCLINE OR A PHARMACOLOGICALLY ACCEPTABLE ORGANIC OR INORGANIC SALT OR METAL COMPLEX THEREOF; REGISTRATION NO/DATE: EU/1/06/336/001 20060424
0620232	01C0054	France	⤷ Subscribe	PRODUCT NAME: CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001 20011024
1273292	C01273292/01	Switzerland	⤷ Subscribe	PRODUCT NAME: TOBRAMYCIN; REGISTRATION NO/DATE: SWISSMEDIC 58751 28.05.2009
0536515	300244	Netherlands	⤷ Subscribe	PRODUCT: TIGECYCLINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF METAALCOMPLEX, IN HET BIJZONDER TIGECYCLINE; FIRST REGISTRATION, DATE: EU/1/06/336/001, 20060424
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.